This non-interventional cross-sectional online survey will evaluate preferences among
patients with self-reported HCC. The survey will ask patients to express their preferences
regarding descriptions of HCC treatments, which will include sorafenib (which will be
described as 'oral anti-cancer therapy'), repeated transarterial chemoembolization (TACE),
and hepatic arterial infusion chemotherapy (HAIC). Please note that all interventions that
patients may have received before completing this online survey were given regardless of
their participation in this survey. Questions also include asking patients to rank various
treatment characteristics (e.g., mechanism of action, risk of adverse effects, etc.) relative
to each other. The ultimate goal is to better understand patient perceptions of these
treatments and to provide evidence to help in patients' and physicians' treatment
decision-making in HCC.